pyrazines has been researched along with Leukoencephalopathy Syndrome, Posterior in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, T; Mitomi, T; Sugamori, H; Yamagishi, C | 1 |
| De Claro, RA; Farrell, AT; Fu, W; Goldberg, KB; Gudi, R; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Przepiorka, D; Pulte, ED; Qosa, H; Wang, Y; Xu, Q | 1 |
| Nixon, NA; Parhar, K | 1 |
| Ho, CH; Lo, CP; Tu, MC | 1 |
| D'Rozario, J; Hanrahan, R; Lueck, C; Terwiel, E | 1 |
| Doki, N; Endo, I; Kakihana, K; Kamata, N; Kobayashi, T; Kojima, A; Ohashi, K; Oshikawa, G; Sakamaki, H; Tsuda, H | 1 |
| Kalachand, R; Kelly, K; Murphy, P | 1 |
1 review(s) available for pyrazines and Leukoencephalopathy Syndrome, Posterior
| Article | Year |
|---|---|
Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Recovery of Function; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2013 |
1 trial(s) available for pyrazines and Leukoencephalopathy Syndrome, Posterior
| Article | Year |
|---|---|
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2021 |
5 other study(ies) available for pyrazines and Leukoencephalopathy Syndrome, Posterior
| Article | Year |
|---|---|
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.
Topics: Aniline Compounds; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrazines | 2022 |
Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neuroimaging; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2014 |
Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Syndrome | 2014 |
Reversible posterior encephalopathy syndrome associated with bortezomib.
Topics: Boronic Acids; Bortezomib; Female; Humans; Hypertensive Encephalopathy; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2010 |
Bortezomib-induced reversible posterior leucoencephalopathy syndrome.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Magnetic Resonance Imaging; Male; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2008 |